Did CEOs and officers buy or sell their own stock?
Open-market trades by the people who know the company best, with their own money.
Last 7 days: the stocks insiders bought and sold most
Stocks Koreans hold most · disclosed Last 7 days · open-market trades only
Bought most
Sold most
Whalegun
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Karen FirestoneDirector | Amylyx PharmaceuticalsAMLX | Open-market buy | 05/21 | 05/26 | 3,800 sh | $13.51 | $51,338 | +6.0% |
Amylyx PharmaceuticalsAMLX | Open-market sale | 03/02 | 03/04 | 7,909 sh | $14.52 | $114,838.68 | −4.6% | |
Camille L. BedrosianChief Medical Officer | Amylyx PharmaceuticalsAMLX | Open-market sale | 03/02 | 03/04 | 6,461 sh | $14.58 | $94,201.38 | −3.7% |
Justin B. KleeCo-CEO | Amylyx PharmaceuticalsAMLX | Open-market sale | 03/02 | 03/04 | 29,282 sh | $14.47 | $423,710.54 | −0.9% |
Joshua B. CohenCo-CEO | Amylyx PharmaceuticalsAMLX | Open-market sale | 03/02 | 03/04 | 29,282 sh | $14.48 | $424,003.36 | −0.9% |
Gina MazzarielloChief Legal Officer | Amylyx PharmaceuticalsAMLX | Open-market sale | 03/02 | 03/04 | 6,844 sh | $14.52 | $99,374.88 | −4.8% |
Gina MazzarielloChief Legal Officer | Amylyx PharmaceuticalsAMLX | Open-market sale | 02/23 | 02/25 | 3,419 sh | $14.14 | $48,344.66 | −2.4% |
Amylyx PharmaceuticalsAMLX | Open-market sale | 02/02 | 02/04 | 3,557 sh | $14.65 | $52,110.05 | −2.0% | |
Justin B. KleeCo-CEO | Amylyx PharmaceuticalsAMLX | Open-market sale | 02/02 | 02/04 | 15,500 sh | $14.69 | $227,695 | −0.5% |
Joshua B. CohenCo-CEO | Amylyx PharmaceuticalsAMLX | Open-market sale | 02/02 | 02/04 | 15,500 sh | $14.68 | $227,540 | −0.5% |
Gina MazzarielloChief Legal Officer | Amylyx PharmaceuticalsAMLX | Open-market sale | 02/02 | 02/04 | 3,448 sh | $14.65 | $50,513.2 | −2.3% |
Amylyx PharmaceuticalsAMLX | Open-market sale | 01/15–01/16 | 01/20 | 138,188 sh2 trades | $13.58avg. | $1,877,211.49 | −3.9% | |
Amylyx PharmaceuticalsAMLX | Open-market sale | 01/15–01/16 | 01/20 | 138,167 sh2 trades | $13.59avg. | $1,878,163.29 | −3.9% | |
Amylyx PharmaceuticalsAMLX | Open-market sale | 01/06 | 01/08 | 3,326 sh | $11.11 | $36,951.86 | −1.8% | |
Justin B. KleeCo-CEO | Amylyx PharmaceuticalsAMLX | Open-market sale | 01/06 | 01/08 | 7,715 sh | $11.09 | $85,559.35 | −0.2% |
Joshua B. CohenCo-CEO | Amylyx PharmaceuticalsAMLX | Open-market sale | 01/06 | 01/08 | 7,715 sh | $11.09 | $85,559.35 | −0.2% |
Karen FirestoneDirector | Amylyx PharmaceuticalsAMLX | Open-market buy | 25/12/23 | 25/12/23 | 8,100 sh | $12.45 | $100,845 | +14.7% |
Camille L. BedrosianChief Medical Officer | Amylyx PharmaceuticalsAMLX | Open-market sale | 25/12/01 | 25/12/03 | 6,580 sh | $14.35 | $94,423 | −3.6% |
Amylyx PharmaceuticalsAMLX | Open-market sale | 25/09/30 | 25/10/02 | 10,558 sh | $14.65 | $154,674.7 | −3.6% | |
Camille L. BedrosianChief Medical Officer | Amylyx PharmaceuticalsAMLX | Open-market sale | 25/09/30 | 25/10/02 | 12,039 sh | $14.58 | $175,528.62 | −6.2% |